One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo
Withdrawals due to adverse events · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
- RR 0.46 [0.04, 4.98]1 study · 131 participantsLow